lopinavir/ritonavir / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 77 Diseases   69 Trials   69 Trials   4434 News 


«12345678910111213...4546»
  • ||||||||||  ivermectin oral / Generic mfg.
    Journal, Real-world evidence, Real-world:  Real-world prescription of anti-COVID-19 drugs in hospitalized patients with COVID-19 in Japan. (Pubmed Central) -  Jan 30, 2024   
    A prescribed drug would depend on the latest scientific evidence, such as efficacy, safety, and approval status, at the time of prescription. Understanding the prescription of anti-COVID-19 drugs will be important for providing the most up-to-date treatments to patients and evaluating the benefit and/or risk of anti-COVID-19 drugs based on the utilization of an electronic medical record database.
  • ||||||||||  Review, Journal:  A Review of Thyroid Dysfunction due to COVID-19. (Pubmed Central) -  Jan 30, 2024   
    These changes can be confusing for clinicians and can lead to inappropriate diagnoses and decisions. Prospective studies should be conducted in the future to increase epidemiological and clinical data and optimize the management of thyroid dysfunctions in patients with COVID-19.
  • ||||||||||  Trial completion date, Trial primary completion date:  Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum (clinicaltrials.gov) -  Jan 29, 2024   
    P=N/A,  N=325, Recruiting, 
    Prospective studies should be conducted in the future to increase epidemiological and clinical data and optimize the management of thyroid dysfunctions in patients with COVID-19. Trial completion date: Oct 2025 --> Mar 2026 | Trial primary completion date: Oct 2025 --> Mar 2026
  • ||||||||||  Lagevrio (molnupiravir) / Ridgeback Biotherap, Merck (MSD)
    Review, Journal:  After the Hurricane: Anti-COVID-19 Drugs Development, Molecular Mechanisms of Action and Future Perspectives. (Pubmed Central) -  Jan 27, 2024   
    Other therapeutics, including inhaled medicines, flavonoids, and aptamers, could pave the way for the creation of novel anti-COVID-19 therapies. As future pandemics are unavoidable, this article urges immediate action and extensive research efforts to develop potent specialized anti-COVID-19 medications.
  • ||||||||||  ivermectin oral / Generic mfg.
    Review, Journal:  Obesity and its Relationship with Covid-19: A Review of the Main Pharmaceutical Aspects. (Pubmed Central) -  Jan 23, 2024   
    Several drugs have been suggested to control COVID- 19 like Lopinavir, Ritonavir, Ribavirin, Sofosbuvir, Remdesivir, Oseltamivir, Oseltamivir phosphate, Oseltamivir carboxylate, Hydroxychloroquine, Chloroquine, Azithromycin, Teicoplanin, Tocilizumab, Anakinra, Methylprednisolone, Prednisolone, Ciclesonide and Ivermectin...Additionally, different aspects make the obese population more prone to persistent symptoms of the disease (long COVID), which makes understanding these mechanisms fundamental to addressing the implications of the disease. Thus, this review provides an overview of the relationship between COVID-19 and obesity, considering aspects related to pharmacokinetics, immunosuppression, immunization, and possible implications of long COVID in these individuals.
  • ||||||||||  Phase classification, Enrollment change, Trial completion date, Trial primary completion date:  RECOVERY: Randomised Evaluation of COVID-19 Therapy (clinicaltrials.gov) -  Jan 5, 2024   
    P3,  N=70000, Recruiting, 
    Further studies are needed to assess the acceptability of other medications in chronically ill children. Phase classification: P2/3 --> P3 | N=50000 --> 70000 | Trial completion date: Nov 2032 --> Jun 2036 | Trial primary completion date: Nov 2023 --> Jun 2026
  • ||||||||||  bictegravir (GS-9883) / Gilead, Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead, Vitekta (elvitegravir) / Japan Tobacco, Gilead
    Retrospective data, Journal:  Reasons, safety and efficacy analysis for conversion of HAART to TAF/FTC/BIC among HIV-infected patients. (Pubmed Central) -  Dec 28, 2023   
    The transition to TAF/FTC/BIC demonstrated good treatment potency. Furthermore, this study elucidates the motivations behind the adoption of TAF/FTC/BIC in real-world scenarios, providing clinical evidence supporting the stable conversion to TAF/FTC/BIC for HAART-experienced patients.
  • ||||||||||  Evusheld (cilgavimab/tixagevimab) / AstraZeneca, Rebif (human IFN-?-1a) / EMD Serono
    Trial completion, Enrollment change:  DisCoVeRy: Trial of Treatments for COVID-19 in Hospitalized Adults (clinicaltrials.gov) -  Nov 29, 2023   
    P3,  N=1552, Completed, 
    The NAC could be more effective as prophylactic or adjuvant therapy in stable non-severe cases of COVID-19 with a particularly positive role in the augmentation of O saturation and faster reduction of the CRP level and inflammation or could be effective for better controlling of COVID-19 or its therapy-related side effects. Active, not recruiting --> Completed | N=2416 --> 1552
  • ||||||||||  Review, Journal:  New-Onset Atrial Fibrillation in the Critically Ill COVID-19 Patients Hospitalized in the Intensive Care Unit. (Pubmed Central) -  Nov 25, 2023   
    Lastly, the management of NOAF in these patients has not been extensively studied. Nevertheless, the current guidelines for NOAF in non-COVID ICU patients appear to be effective, while accounting for the specific drugs used in COVID-19 treatment that may prolong the QT interval (although drugs like lopinavir/ritonavir, hydrochlorothiazide, and azithromycin have been discontinued) or induce bradycardia (e.g., remdesivir).
  • ||||||||||  ivermectin oral / Generic mfg.
    Review, Journal:  Assessing the Potential Contribution of In Silico Studies in Discovering Drug Candidates That Interact with Various SARS-CoV-2 Receptors. (Pubmed Central) -  Nov 18, 2023   
    In silico studies have identified several promising drug candidates, including Remdesivir, Favipiravir, Ribavirin, Ivermectin, Lopinavir/Ritonavir, and Camostat Mesylate, among others...This study is aimed at assessing the useful contributions of the application of computational instruments in the discovery of receptors targeted in SARS-CoV-2. It further highlights some identified advantages and limitations of these studies, thereby revealing some complementary experimental validation to ensure the efficacy and safety of identified drug candidates.
  • ||||||||||  ivermectin oral / Generic mfg.
    Clinical, Retrospective data, Review, Journal:  Efficacy and Safety of Novel Oral Antivirals in Hospitalized COVID-19 Patients: A Network Meta-Analysis of Randomized Clinical Trials. (Pubmed Central) -  Nov 7, 2023   
    We searched for randomized clinical trials (RCTs) on the efficacy and safety of novel oral antivirals for the treatment of hospitalized COVID-19 patients until November 30, 2022, including baricitinib, ivermectin (IVM), favipiravir (FVP), chloroquine (CQ), lopinavir and ritonavir (LPV/RTV), hydroxychloroquine (HCQ), and hydroxychloroquine plus azithromycin (HCQ+AZT)...IVM appeared to be a safer option than placebo in improving recovery time, while FVP was associated with increased SpO2 safety outcomes. These preliminary evidence-based observations should guide clinical practice until more data are made public.
  • ||||||||||  bromhexine hydrochloride / Generic mfg.
    Clinical, Journal:  Effect of bromhexine in hospitalized patients with COVID-19. (Pubmed Central) -  Oct 22, 2023   
    Bromhexine is not an effective treatment for hospitalized patients with COVID-19. The potential prevention benefits of bromhexine in asymptomatic postexposure or with mild infection managed in the community remain to be determined.
  • ||||||||||  lopinavir/ritonavir / Generic mfg.
    Enrollment open:  Lopinavir/Ritonavir in PLWH With High-Grade AIN (clinicaltrials.gov) -  Sep 14, 2023   
    P1,  N=21, Recruiting, 
    Treatment with these ineffective drugs tended to be prolonged in severely ill patients and in primary and public hospitals. Suspended --> Recruiting
  • ||||||||||  lopinavir/ritonavir / Generic mfg.
    Journal:  Anti-HIV Drugs Lopinavir/Ritonavir Activate Bitter Taste Receptors. (Pubmed Central) -  Sep 11, 2023   
    We discovered that lopinavir activates TAS2R1 and TAS2R13, while ritonavir activates TAS2R1, TAS2R8, TAS2R13, and TAS2R14. The development of bitter taste blockers that target these receptors with a safe profile would be highly desirable in eliminating the unpleasant bitter taste of these anti-HIV drugs.
  • ||||||||||  lopinavir/ritonavir / Generic mfg.
    Trial suspension:  Lopinavir/Ritonavir in PLWH With High-Grade AIN (clinicaltrials.gov) -  Sep 6, 2023   
    P1,  N=21, Suspended, 
    However, due to limited study details and significant heterogeneity in effect estimates, further precise evidence is crucial, especially concerning emerging variants. Recruiting --> Suspended
  • ||||||||||  Tivicay (dolutegravir) / ViiV Healthcare
    Observational data, Retrospective data, Journal:  Optimizing antiretroviral therapy for children living with HIV: Experience from an observational cohort in Lesotho. (Pubmed Central) -  Jul 21, 2023   
    The subtherapeutic lopinavir exposures on standard dosing after antituberculosis treatment are of concern and requires further evaluation. Following optimal ART introduction in Lesotho, most children in the cohort were transitioned and many attained or maintained viral suppression after transition; however, we recommend more robust viral load monitoring and patient tracking to reduce losses and improve outcomes after ART transition.
  • ||||||||||  Edurant (rilpivirine) / J&J, Tivicay (dolutegravir) / ViiV Healthcare, Isentress (raltegravir) / Merck (MSD)
    Journal:  Identification of integrase inhibitor-related drug resistance mutations in newly diagnosed ART-na (Pubmed Central) -  Jul 10, 2023   
    Different stakeholders working on the HIV program should maintain viral resuppression by addressing significant predictors, and ART clinicians should consider ritonavir-boosted lopinavir based second-line ART for newly switched patients. In summary, this study is the first to have surveyed the prevalence of integrase inhibitor resistance-related mutations and other drug resistance-related mutations among newly diagnosed ART-na
  • ||||||||||  CinnoVex (IFN-?-1a biosimilar) / CinnaGen
    Journal:  The effect of interferon in the therapy of severe coronavirus infection. (Pubmed Central) -  Jul 3, 2023   
    In summary, this study is the first to have surveyed the prevalence of integrase inhibitor resistance-related mutations and other drug resistance-related mutations among newly diagnosed ART-na Based on the results of this study, the use of interferon in the treatment of COVID-19 can improve health and reduce the severity of the disease and mortality.
  • ||||||||||  Drug induced lupus erythematosus in a HIV infected child, a rare case report () -  Jul 3, 2023 - Abstract #WCD2023WCD_5242;    
    OBSERVATION: A 12 years male child on ART consisting of Lamivudine, Efavirenz and Abacavir for the past five years was brought to the skin outpatient department with fever, non-scaly dusky macular lesions over face, trunk, upper limbs, multiple ulcers and crusted erosions over the lips and hard palate since 7 days...He was managed with Tablet Hydroxychloroquine 50 mg BD and oral Prednisolone syrup starting at 10 mg/day with slow tapering and revised ART consisting of Zidovudine, Lamivudine, Lopinavir and Ritonavir...Drugs causing DILE are procainamide, hydralazine, penicillamine, isoniazid, quinidine, interferon alpha, methyldopa, diltiazem and chlorpromazine. The immunological profile of patients with DILE reveals positive ANA antibodies with homogeneous pattern, positive anti-histone antibodies, negative anti-Smith and generally low or absent anti-double stranded DNA antibodies.